Boston Scientific

Boston Scientific is a global medical device company, the 8th largest (based on annual sales, which were over $8 billion in 2010). It is the world's second largest maker of heart devices; prod...

Cancer

Cancer (malignant neoplasm) is a class of disease. There are malignancy properties that cancer cells have;  1. The diseased tissue grows uncontrollably, ignoring growth arrest signals, ...

Stem Cells

Stem cells can be found in all multicellular organisms and are characterized by the ability to renew themselves through mitotic cell division and differentiate into a diverse range of specialized ce...

Sanofi-Aventis

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

[Cyclacel] and [Celgene] settle patent litigation surrounding {Istodax}

Cancer drug developers [Cyclacel Pharmaceuticals Inc.] and [Celgene Corp.] have settled three-year-old patent litigation surrounding romidepsin, the main drug in Celgene’s {Istodax}, which is market...

Celgene Int'l Sàrl Announces Results From Several Studies

SUMMIT (dpa-AFX) - Celgene International Sàrl, a subsidiary of Celgene Corp. (CELG), announced results from several studies evaluating combination treatment with Revlimid (lenalidomide) and antibo...

Celgene: The Biopharma Stock You Need In Your Portfolio

ByDarius Samz:Celgene (CELG) has recently hit its 52 week high after a long upward trend and has confirmed an expected 13% growth for 2013. So is Celgene a buy, sell or hold? I still think it is a buy...

Figure: Celgene's buybacks

Ebb & Flow Celgene's buybacks Celgene Corp. (NASDAQ:CELG) continues to see stock buybacks as a way to create shareholder value, announcing on June 13 that its board authorized a repurchase of up to $2...

Celgene

Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey. The company was born in 1986 as a spin out from Celanese Corporation, following the merger o...

Celgene Corporation Presents at 31st Annual JPMorgan Healthcare Conference, Jan-07-2013 08:00 AM

Celgene Corporation (CELG) January 07, 2013 11:00 am ET Executives Robert J. Hugin - Chairman, Chief Executive Officer, President and Chairman of Executive Committee Analysts Geoffrey C. Meach...

Celgene Corporation to Present at the 31st Annual J.P. Morgan Healthcare Conference

Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 31st Annual J.P. Morgan Healthcare Conference on January 7, 2013 at 11:00a.m. E.T. will be webcast live...

Celgene's Apremilast Achieves Statistical Significance In Psoriasis Patients

SUMMIT (dpa-AFX) - Celgene International Sàrl, a part of Celgene Corp. (CELG), Saturday presented the results from ESTEEM 1, the company's first phase III study in psoriasis, at the American Acade...

Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective.

Celgene has developed and operated pregnancy prevention programs since 1998 with the first approval of thalidomide in the US. With the development and marketing of lenalidomide, an analog of thalidomi...

Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.

We report here the discovery of a novel series of selective mTOR kinase inhibitors and the identification of CC214-2, a compound with demonstrated anti-tumor activity upon oral dosing in a PC3 prostat...

Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs.

Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.

PURPOSE: To evaluate the pharmacokinetics and cardiac repolarization effect (measured by QT/QTc interval) of amrubicin and its active metabolite amrubicinol in non-Japanese patients with advanced soli...

Pomalidomide: First Global Approval.

Pomalidomide (Pomalyst(®)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases. Pomalidomide...